NCT00092001View on ClinicalTrials.gov

Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Sunitinib

Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.

Trial Locations (14)

10043

Pfizer Investigational Site, Orbassano (Torino)

15232

Pfizer Investigational Site, Pittsburgh

22908

Pfizer Investigational Site, Charlottesville

27534

Pfizer Investigational Site, Goldsboro

27893

Pfizer Investigational Site, Wilson

28382

Pfizer Investigational Site, Clinton

28573

Pfizer Investigational Site, Pollocksville

63110

Pfizer Investigational Site, St Louis

63376

Pfizer Investigational Site, City of Saint Peters

21231-1000

Pfizer Investigational Site, Baltimore

63110-1094

Pfizer Investigational Site, St Louis

27599-7600

Pfizer Investigational Site, Chapel Hill

08916

Pfizer Investigational Site, Badalona

08025

Pfizer Investigational Site, Barcelona

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY